ES2173902T3 - Composiciones topicas que contienen bencimidazoles y benzotriazoles. - Google Patents

Composiciones topicas que contienen bencimidazoles y benzotriazoles.

Info

Publication number
ES2173902T3
ES2173902T3 ES94200665T ES94200665T ES2173902T3 ES 2173902 T3 ES2173902 T3 ES 2173902T3 ES 94200665 T ES94200665 T ES 94200665T ES 94200665 T ES94200665 T ES 94200665T ES 2173902 T3 ES2173902 T3 ES 2173902T3
Authority
ES
Spain
Prior art keywords
bencimidazols
benzotriazols
compositions containing
topical compositions
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94200665T
Other languages
English (en)
Inventor
Wauwe Jean Pierre Frans Van
Alfons Herman Marg Raeymaekers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2173902T3 publication Critical patent/ES2173902T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA O COSMETICA QUE COMPRENDE UN PORTADOR INERTE, UNA CANTIDAD EFECTIVA DE ACIDO RETINOICO O UN DERIVADO DE MISMO, O UNA FORMA ESTEREOQUIMICAMENTE ISOMERICA DEL MISMO Y UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE LA FORMULA (I) O DE UN COMPUESTO DE LA FORMULA (II), UNA SAL DE ADICION ACIDA DE LOS MISMOS O UNA FORMA ESTEREROQUIMICAMENTE ISOMERICA DE LOS MISMOS. TAMBIEN SE PRESENTA SU USO PARA LA MANUFACTURA PARA SUJETOS DE TRATAMIENTO QUE SUFRAN DE ENFERMEDADES QUE SE CARACTERICEN POR UNA PROLIFERACION INCREMENTADA Y/O UNA DIFERENCIACION ANORMAL DE CELULAS EPITELIALES NORMALES, PRENEOPLASTICAS O NEOPLASTICAS, CUYO CRECIMIENTO ES SENSIBLE A LA ACCION DE LOS RETINOIDES.
ES94200665T 1988-11-29 1989-11-27 Composiciones topicas que contienen bencimidazoles y benzotriazoles. Expired - Lifetime ES2173902T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27715288A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
ES2173902T3 true ES2173902T3 (es) 2002-11-01

Family

ID=23059616

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94200665T Expired - Lifetime ES2173902T3 (es) 1988-11-29 1989-11-27 Composiciones topicas que contienen bencimidazoles y benzotriazoles.
ES89203001T Expired - Lifetime ES2065369T3 (es) 1988-11-29 1989-11-27 Uso de bencimidazoles en el tratamiento de enfermedades epiteliales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES89203001T Expired - Lifetime ES2065369T3 (es) 1988-11-29 1989-11-27 Uso de bencimidazoles en el tratamiento de enfermedades epiteliales.

Country Status (16)

Country Link
EP (2) EP0371559B1 (es)
JP (2) JP2752200B2 (es)
AT (2) ATE213941T1 (es)
AU (2) AU623454B2 (es)
CA (1) CA2002859C (es)
CY (1) CY1867A (es)
DE (2) DE68918809T2 (es)
DK (1) DK175793B1 (es)
ES (2) ES2173902T3 (es)
HK (1) HK114895A (es)
IE (1) IE63877B1 (es)
IL (1) IL92487A (es)
NZ (1) NZ231405A (es)
PT (1) PT92449B (es)
SG (1) SG50466A1 (es)
ZA (1) ZA899074B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
US5663354A (en) * 1992-11-10 1997-09-02 Janssen Pharmaceutica, N.V. Process for preparing enantiomerically pure 6-[(4-chlorophenyl) (1H-1,2,4-triazol-1-yl) methyl]-1-methyl-1H-benzotrizole
MX9603510A (es) * 1994-02-18 1997-03-29 Janssen Pharmaceutica Nv (-)-liarozol enantiomericamente puro.
NZ279227A (en) * 1994-02-18 1997-11-24 Janssen Pharmaceutica Nv Dextrorotatory (+)-5-[3-chlorophenyl]-1h-imidazol-1-ylmethyl]-1h-benzimidazole derivatives (liarozole)
TW316902B (es) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
JPH10511653A (ja) * 1994-12-28 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カルシトリオール代謝の阻害剤としてのベンゾイミダゾール類
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
WO1997006788A1 (en) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Transdermal administration of vorozole
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EE03688B1 (et) 1996-06-27 2002-04-15 Janssen Pharmaceutica N.V. N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks
JPH10220909A (ja) 1996-12-03 1998-08-21 Komatsu Ltd 流体温度制御装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
AU2160899A (en) 1997-12-11 1999-06-28 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
ATE262520T1 (de) * 1998-06-16 2004-04-15 Sod Conseils Rech Applic Imidazol-derivate
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
EP1173148A4 (en) * 1999-04-29 2002-07-24 Avon Prod Inc METHOD FOR IMPROVING THE AESTHETIC APPEARANCE OF THE EPITHEL
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
FR2815857B1 (fr) * 2000-10-30 2003-02-14 Oreal Composition, notamment cosmetique, renfermant un retinoide et une silicone benzotriazole
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2504448C (en) * 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
CA2785536C (en) 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
CN103748093B (zh) 2011-06-24 2016-06-01 艾科尔公司 被取代的咪唑并吡啶基-氨基吡啶化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders

Also Published As

Publication number Publication date
EP0371559B1 (en) 1994-10-12
CY1867A (en) 1996-04-05
DE68929377D1 (de) 2002-04-11
DE68918809D1 (de) 1994-11-17
IE893781L (en) 1990-05-29
ES2065369T3 (es) 1995-02-16
DK599589A (da) 1990-05-30
DE68918809T2 (de) 1995-03-23
CA2002859C (en) 1998-12-29
JPH1095782A (ja) 1998-04-14
HK114895A (en) 1995-07-21
PT92449A (pt) 1990-05-31
IE950033L (en) 1990-05-29
DK175793B1 (da) 2005-02-21
EP0371559A3 (en) 1992-04-08
EP0609963B1 (en) 2002-03-06
AU4564889A (en) 1990-06-07
SG50466A1 (en) 1998-07-20
ATE112681T1 (de) 1994-10-15
JP2752200B2 (ja) 1998-05-18
EP0371559A2 (en) 1990-06-06
IE63877B1 (en) 1995-06-14
IL92487A0 (en) 1990-08-31
JP2912596B2 (ja) 1999-06-28
AU630579B2 (en) 1992-10-29
DK599589D0 (da) 1989-11-28
IL92487A (en) 1994-12-29
CA2002859A1 (en) 1990-05-29
AU1071692A (en) 1992-03-19
ZA899074B (en) 1991-07-31
ATE213941T1 (de) 2002-03-15
EP0609963A1 (en) 1994-08-10
PT92449B (pt) 1995-07-18
AU623454B2 (en) 1992-05-14
NZ231405A (en) 1991-08-27
JPH0320273A (ja) 1991-01-29
DE68929377T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2173902T3 (es) Composiciones topicas que contienen bencimidazoles y benzotriazoles.
ATE81975T1 (de) Arzneimittel mit psychotroper wirkung.
MX9304996A (es) Heterociclos no-aromaticos que contienen bencilamino nitrogeno substituido.
MX9307810A (es) Heterociclicos no aromaticos sustituidos con aminometileno.
NO180719C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive A-nor-steroid-3-carboxylsyrederivater
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NZ239844A (en) Retinoic acid derivatives and pharmaceutical compositions thereof
ES8206455A1 (es) Procedimiento para la preparacion de derivados de guanidina
FI963168A (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia
ES2017633B3 (es) Amido derivados.
ATE73330T1 (de) Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen.
ATE167869T1 (de) Thiolderivate von gallensäure
ES8504736A1 (es) Un procedimiento para la preparacion de compuestos de imidazolilpropanol opticamente activos
FR2382901A1 (es)
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
FR2414333A2 (fr) Composition pharmaceutique contenant comme ingredient actif la d-2-bromo 6-methyl-8b-(morpholinocarbonyoxymethyl)-ergoline, utile notamment pour le traitement de l'asthme
JPS6452772A (en) Pyridylpyrimidine derivative, production thereof and plant disease controlling agent containing said derivative as active ingredient
ATE11012T1 (de) Ophthalmische zusammensetzung, die 5-fluor-2methyl-1-(p-methylthio-benzyliden)-3-indenylessigs[ure oder deren salz enthaelt.
FR2364885A1 (fr) Acides phenoxyphenoxyvaleriques et leurs derives, compositions les renfermant et procede de leur utilisation comme herbicides
DE68903188D1 (de) Acylsulfonamid-derivate von alpha-carbocyclyltoluylsaeuren und ihre verwendung als leukotrienantagonisten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 609963

Country of ref document: ES